New York (March 6th, 2013) - Halliburton Company (NYSE:HAL) posted similar results to Schlumberger, a decrease in profits but an increase in revenues, even though the fall was far greater and the increase in revenues was much smaller as compared to Schlumberger.
The company’s revenues climbed by a more modest 3.3% to $7.29 billion, while its net income fell by 26.2% to $669 million or $0.72 per share. Analysts were expecting earnings of $0.61 per share.
Despite the company’s heavy exposure to North America, a region where drilling activity was down in Q4-2012, Halliburton’s revenues still increased due to strong performances from Middle East/Asia and Latin America regions.
HAL is a part of the Energy sector, which includes companies such as Schlumberger N.V. (SLB) and Oceaneering International, Inc. (OII).
Find out if this is the moment investors have been waiting for before trading HAL here:
Gilead Sciences Inc. (NASDAQ:GILD) announced detailed 24-week results from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen containing tenofoviralafenamide (TAF) for the treatment of HIV-1 infection.
A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovirdisoproxilfumarate 300 mg) based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment.
These findings were presented in a latebreaker session (Abstract #99LB) at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) taking place in Atlanta.
Find out more on GILD by getting the free and full daily trend analysis report here:
Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.